Daewoong pharmaceutical Co.,Ltd (069620.KS)
KRW 125500.0
(-2.64%)
KRW 125500.0
(-2.64%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 10.65 Thousand KRW | 179.25% |
| 2022 | 3815.95 KRW | 71.36% |
| 2021 | 2226.87 KRW | -1.67% |
| 2020 | 2264.77 KRW | 6.22% |
| 2019 | 2132.18 KRW | 245.24% |
| 2018 | -1468.08 KRW | -147.98% |
| 2017 | 3060.00 KRW | 17.11% |
| 2016 | 2613.00 KRW | -37.19% |
| 2015 | 4160.00 KRW | 36.13% |
| 2014 | 3056.00 KRW | -45.99% |
| 2013 | 5658.00 KRW | 71.35% |
| 2012 | 3302.00 KRW | -33.93% |
| 2011 | 4998.06 KRW | 197.89% |
| 2010 | 1677.82 KRW | -64.02% |
| 2009 | 4663.56 KRW | 52.19% |
| 2008 | 3064.39 KRW | -43.37% |
| 2007 | 5411.14 KRW | 22.05% |
| 2006 | 4433.64 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | 707.86 KRW | -87.66% |
| 2024 Q2 | 99.11 KRW | -86.0% |
| 2023 FY | - KRW | 179.25% |
| 2023 Q1 | 1378.78 KRW | 234.22% |
| 2023 Q4 | 5736.73 KRW | 323.71% |
| 2023 Q3 | 1353.93 KRW | -37.04% |
| 2023 Q2 | 2150.33 KRW | 55.96% |
| 2022 Q3 | 1852.19 KRW | 17.37% |
| 2022 Q4 | -1027.24 KRW | -155.46% |
| 2022 FY | - KRW | 71.36% |
| 2022 Q2 | 1578.06 KRW | 28.26% |
| 2022 Q1 | 1230.32 KRW | -55.6% |
| 2021 Q3 | 991.00 KRW | 79.2% |
| 2021 Q1 | -2139.00 KRW | -231.16% |
| 2021 Q2 | 553.00 KRW | 125.85% |
| 2021 Q4 | 2771.11 KRW | 179.63% |
| 2021 FY | - KRW | -1.67% |
| 2020 Q4 | 1630.79 KRW | 631.3% |
| 2020 Q1 | 65.00 KRW | -86.4% |
| 2020 FY | - KRW | 6.22% |
| 2020 Q3 | 223.00 KRW | 130.46% |
| 2020 Q2 | -732.00 KRW | -1226.15% |
| 2019 FY | - KRW | 245.24% |
| 2019 Q1 | 567.00 KRW | 121.77% |
| 2019 Q3 | 153.00 KRW | -86.19% |
| 2019 Q4 | 477.85 KRW | 212.32% |
| 2019 Q2 | 1108.00 KRW | 95.41% |
| 2018 Q3 | 318.00 KRW | -42.08% |
| 2018 FY | - KRW | -147.98% |
| 2018 Q1 | 269.00 KRW | -76.81% |
| 2018 Q2 | 549.00 KRW | 104.09% |
| 2018 Q4 | -2604.95 KRW | -919.17% |
| 2017 Q1 | 318.00 KRW | -78.98% |
| 2017 FY | - KRW | 17.11% |
| 2017 Q4 | 1159.86 KRW | 33.47% |
| 2017 Q3 | 869.00 KRW | -21.64% |
| 2017 Q2 | 1109.00 KRW | 248.74% |
| 2016 FY | - KRW | -37.19% |
| 2016 Q1 | 273.00 KRW | -36.37% |
| 2016 Q4 | 1512.79 KRW | 280.1% |
| 2016 Q3 | 398.00 KRW | -7.23% |
| 2016 Q2 | 429.00 KRW | 57.14% |
| 2015 FY | - KRW | 36.13% |
| 2015 Q1 | 1099.00 KRW | 12.58% |
| 2015 Q2 | 1242.00 KRW | 13.01% |
| 2015 Q3 | 1010.00 KRW | -18.68% |
| 2015 Q4 | 429.03 KRW | -57.52% |
| 2014 Q1 | 1194.00 KRW | 26.95% |
| 2014 FY | - KRW | -45.99% |
| 2014 Q3 | -548.00 KRW | -138.21% |
| 2014 Q4 | 976.18 KRW | 278.14% |
| 2014 Q2 | 1434.00 KRW | 20.1% |
| 2013 Q2 | 1638.00 KRW | 41.82% |
| 2013 Q1 | 1155.00 KRW | 7.26% |
| 2013 FY | - KRW | 71.35% |
| 2013 Q4 | 940.50 KRW | -51.14% |
| 2013 Q3 | 1925.00 KRW | 17.52% |
| 2012 FY | - KRW | -33.93% |
| 2012 Q1 | 1153.40 KRW | 57.22% |
| 2012 Q2 | 443.69 KRW | -61.53% |
| 2012 Q3 | 608.74 KRW | 37.2% |
| 2012 Q4 | 1076.85 KRW | 76.9% |
| 2011 Q4 | 733.62 KRW | -47.77% |
| 2011 FY | - KRW | 197.89% |
| 2011 Q3 | 1404.47 KRW | -17.13% |
| 2011 Q2 | 1694.79 KRW | 28.06% |
| 2011 Q1 | 1323.40 KRW | 0.0% |
| 2010 Q2 | -1059.73 KRW | -172.27% |
| 2010 FY | - KRW | -64.02% |
| 2010 Q3 | 1471.55 KRW | 238.86% |
| 2010 Q1 | 1466.35 KRW | -4.49% |
| 2009 Q4 | 1535.31 KRW | 59.85% |
| 2009 FY | - KRW | 52.19% |
| 2009 Q3 | 960.45 KRW | 38.23% |
| 2009 Q2 | 694.80 KRW | 88.05% |
| 2009 Q1 | 369.47 KRW | -29.55% |
| 2008 FY | - KRW | -43.37% |
| 2008 Q3 | 933.34 KRW | -24.34% |
| 2008 Q1 | 1196.79 KRW | -27.92% |
| 2008 Q2 | 1233.53 KRW | 3.07% |
| 2008 Q4 | 524.47 KRW | -43.81% |
| 2007 Q2 | 1134.68 KRW | 0.0% |
| 2007 FY | - KRW | 22.05% |
| 2007 Q4 | 1660.41 KRW | 16.69% |
| 2007 Q3 | 1422.89 KRW | 25.4% |
| 2006 FY | - KRW | 0.0% |